{"slug":"adjuvant","tag":"adjuvant","variants":["adjuvant"],"description":"No description yet","count":7,"kinds":{"person":7},"related":[{"slug":"immunotherapy","tag":"immunotherapy","shared":4},{"slug":"melanoma","tag":"melanoma","shared":3},{"slug":"colorectal","tag":"colorectal","shared":1},{"slug":"early-phase","tag":"early-phase","shared":1},{"slug":"esophageal","tag":"esophageal","shared":1},{"slug":"lung","tag":"lung","shared":1},{"slug":"trialist","tag":"trialist","shared":1},{"slug":"urothelial","tag":"urothelial","shared":1},{"slug":"vaccine","tag":"vaccine","shared":1}],"records":[{"id":"roy-herbst","kind":"person","name":"Roy S. Herbst","route":"/people/roy-herbst/","tldr":"Lung cancer trialist behind KEYNOTE-010 and the ADAURA adjuvant osimertinib trial."},{"id":"thierry-andre","kind":"person","name":"Thierry André","route":"/people/thierry-andre/","tldr":"Led MOSAIC, which made FOLFOX the adjuvant standard, and KEYNOTE-177, which made pembrolizumab first-line for MSI-high colon cancer."},{"id":"ronan-kelly","kind":"person","name":"Ronan J. Kelly","route":"/people/ronan-kelly/","tldr":"Led CheckMate 577, the first trial to show adjuvant immunotherapy helps oesophageal cancer patients with residual disease."},{"id":"dean-bajorin","kind":"person","name":"Dean F. Bajorin","route":"/people/dean-bajorin/","tldr":"Led CheckMate 274, which established adjuvant nivolumab after bladder cancer surgery."},{"id":"jeffrey-weber","kind":"person","name":"Jeffrey S. Weber","route":"/people/jeffrey-weber/","tldr":"Led CheckMate 238, which made adjuvant nivolumab standard after melanoma surgery, and co-led the mRNA vaccine trial KEYNOTE-942."},{"id":"jason-luke","kind":"person","name":"Jason J. Luke","route":"/people/jason-luke/","tldr":"Led KEYNOTE-716, which extended adjuvant pembrolizumab to high-risk stage II melanoma."},{"id":"john-kirkwood","kind":"person","name":"John M. Kirkwood","route":"/people/john-kirkwood/","tldr":"Pittsburgh melanoma doctor who ran the interferon trials that were the first adjuvant treatment for high-risk melanoma, and later led CheckMate 76K on adjuvant nivolumab for stage II disease."}]}